A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a 2-arm, randomized, open-label, international, multicenter study comparing the
efficacy of DCC-2618 to sunitinib in GIST patients who progressed on or were intolerant to
first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized
in a 1:1 ratio to DCC-2618 150 mg once daily (QD) (continuous dosing for 6 week cycles) or
sunitinib 50 mg QD (6 week cycles, 4 weeks on, 2 weeks off).